PCI Biotech to present at Biotech Showcase 2017

Oslo, Norway, January 6, 2017 PCI Biotech (OSE: PCIB ), a clinical-stage company developing innovative therapeutics that address significant unmet medical needs, today announced that it will present at the 9th Annual Biotech Showcase(TM) 2017 being held January 9-11, 2017 at the Hilton San Francisco Union Square, California, US. Taking place during one of the industry's largest annual healthcare investor conferences, this investor and partnering conference attracts pharmaceutical executives from around the world focused on investment and business development opportunities in the life sciences industry.

On Monday, January 9, 2017 at 4:00pm PT, Dr. Per Walday, PCI Biotech's CEO, will present an overview of the Company's PCI technology and the multiple business development and commercial opportunities available based on this proprietary platform. The presentation will be made available on PCI Biotech's website ( www.pcibiotech.com ) under News.

About PCI Biotech          PCI Biotech is a biopharmaceutical company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform.  PCI is applied to three distinct anticancer paradigms: fima Chem (enhancement of chemotherapeutics for localised treatment of cancer), fima Vacc (T-cell induction technology for therapeutic vaccination), and fima NAc (nucleic acid therapeutics delivery).

Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company's lead fima Chem programme consists of a clinical Phase I/II clinical study in bile duct cancer, an orphan indication with a high unmet need and without approved products.  fima Vacc applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies.  fima NAc utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and siRNA therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field. Contact information:    PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo, Norway. www.pcibiotech.com        Ronny Skuggedal, CFO, rs@pcibiotech.no , Mobile: +47 9400 5757.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.